01/2020 Ventures

News advanceCOR

Congratulations to advanceCOR! With its lead compound Revacept, our portfolio company was able to prevent the local activation of blood platelets at sites of vascular injury in carotid stenosis patients in a phase II clinical trial and thereby achieving an almost 50% reduction in new silent strokes (microinfarctions). More information can be found in the press release under the following link.

More about advanceCOR

01/2020 Ventures

Successful exit Cunesoft

We are happy to start the new year with great news. After nearly four years of investing in Cunesoft and supporting the exciting development of digital data management in the healthcare sector, we could realize a successful exit. With Phlexglobal, Cunesoft has found a perfect match for its further internationalization of its unique software solution. We congratulate the founders and the whole team and wish them all the best!

More information can be found in the press release under the following link.

01/2020 Group

We are climate neutral

Also at the beginning of the year 2020, climate change and its negative consequences are more present than ever. As a sustainable company, this issue is important to us, which is why we also want to make our contribution to climate protection. We have calculated our CO2 corporate balance for the year 2019 and, based on this, support projects to reduce carbon dioxide emissions in cooperation with the Swiss foundation myclimate.

More about myclimate

12/2019 Group

When you raise your eyes, you see no boundaries

(Japanese proverb)

We would like to make ourselves aware at the end of the year that in a fast-moving and continuously success-oriented time it is always necessary to pause for a moment in order to actually be able to realize the unlimited potential of innovation.

With this in mind, we would like to thank you for the enriching and inspiring cooperation and look forward to working together in the future to raise our eyes and improve tomorrow‘s life sustainably through meaningful investments.

We wish you a peaceful, inspiring Christmas season and a fantastic year in 2020.

12/2019 Ventures

Follow-on Investment in Resistell

Resistell closes the year successfully with Occident as lead investor in the Series A financing round. Founded in 2018, the start-up is dedicated to the precise and rapid identification of antibiotic resistance. In order to advance clinical validation and marketing approval, additional funding was provided by existing and new investors. More information can be found in the press release under the following link.

More about Resistell 

12/2019 Ventures

Investment in Algiax Pharmaceuticals

Occident invests in the German clinical-stage biotech start-up Algiax Pharmaceuticals, which develops innovative and unique therapeutics for the treatment of neuropathic pain. More information can be found in the press release under the following link.

More about Algiax

12/2019 Ventures

BioM BioAngels Pitch Day in Munich

Congratulations to BioM for the successful 7th BioAngels Pitch Day in Munich! With the excellent selection of startups BioM proved the exceptional quality of the event again this year. We were happy to support as sponsor and investor expert and are looking forward to the events in the new year.

More about BioM

10/2019 Human Resources

OCCIDENT Workshop in Hamburg

Investing in start-ups is based on mutual trust and good cooperation. Our investment team has grown this year, and so we took the time to professionalize the topic of communication in a workshop in Hamburg. In addition to talking about our own motivation and inspiration for our job, we also had time to get to know each other better away from our everyday work.

Show more